Navigation Links
Low-dose anticoagulation therapy used with new design mechanical heart valve lowers bleeding risk
Date:5/6/2013

Minneapolis, MN, May 6, 2013 For more than 40 years, patients under 65 years of age requiring heart valve replacement have had to choose between a mechanical valve that offers life-long durability but requires aggressive warfarin anticoagulation or a biological (cow or pig) valve that will wear out in 10-20 years but does not require anticoagulation. Aggressive warfarin anticoagulation is accompanied by significant annual risk of bleeding, while inadequate anticoagulation of a mechanical artificial valve has been associated with high risk of clotting problems that can cause strokes.

A newer generation mechanical heart valve, manufactured by On-X Life Technologies, Austin, TX, has several design features that make it more efficient and less likely to clot. The FDA is allowing a randomized trial to be conducted to determine whether it is safe and effective to treat patients with an On-X mechanical aortic valve with less aggressive anticoagulation than has previously been recommended by the American Heart Association and American College of Cardiology.

In an interim report to be presented at the 93rd AATS Annual Meeting in Minneapolis on May 6, 2013, John D. Puskas, MD, Professor and Associate Chief of the Division of Cardiothoracic Surgery, Emory University School of Medicine, Athens, GA, and his co-investigators show that lower dose anticoagulation therapy, combined with low-dose aspirin, resulted in a reduction of 55 to 60% of the incidence of adverse bleeding events without significant increases in stroke, transient ischemic attack or total neurological events when used in conjunction with the On-X mechanical aortic valve.

As part of the Prospective Randomized On-X Anticoagulation Clinical Trial (PROACT), a control group of patients received standard treatment of warfarin administered to maintain a target range of the International Normalized Ratio (INR) of 2.0-3.0. The second treatment group received low-dose warfarin, targeting an INR of 1.5-2.0.

From June 2006 until October 2009, 375 Aortic Valve Replacement (AVR) patients were randomized into control (190) and treatment (185) groups three months after surgery. All patients had received standard therapy for the first 3 months including aspirin 81 mg daily. Mean age was 55.8 years in the control group and 54.1 years in the treatment group. Approximately 80% of the patients were male and 93% were in sinus rhythm before valve replacement. Patients were followed for an average of 3.82 years.

Dr. Puskas concludes that "Anticoagulation may be safely reduced in AVR patients after implantation of this approved bileaflet mechanical prosthesis. In combination with low-dose aspirin, this therapy resulted in significantly lower risk of bleeding than customary aggressive anticoagulation, without significant increase in clots or strokes."


'/>"/>

Contact: Nicole Baritot
press@aats.org
978-299-4520
American Association for Thoracic Surgery
Source:Eurekalert

Related medicine news :

1. Low-Dose Pill Linked to Pain During Orgasm, Study Finds
2. Resistance to low-dose aspirin therapy extremely rare
3. Maturitas publishes clinical guide on low-dose vaginal estrogens for vaginal atrophy
4. Low-dose CT screening may benefit individuals at increased risk for lung cancer
5. Low-dose whole-body CT finds disease missed on standard imaging for patients with multiple myeloma
6. CWRU School of Medicine researchers discover new target for personalized cancer therapy
7. Women's Excellence in Menopause Now Offering Treatment Options for Decreased Sex Drive near Rochester Hills, Michigan; Natural Therapy Available via Bioidentical Hormones
8. TherapySites and the AAMFT are Offering an Educational Webinar, "4 Online Marketing Trends You Can't Afford To Ignore"
9. North American Seminars Introduces Vestibular Rehabilitation - Examination and Treatment, a New Physical Therapy Online Continuing Education Course
10. Clarifying the effect of stem cell therapy on cancer
11. Get Rid of Varicose Veins in Time for Summer with Shaft Medical San Diego’s Micro Needle Sclerotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... Gateway ... now offering HIAC particle counting and sizing services for USP 788 and 789 ... the new service as a response to the needs of pharmaceutical and medical ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... 'Tis the ... disrupt daily routines. That means it's also the season when eating healthy, staying active, ... with diabetes) on schedule is harder to do. , "Shopping trips, parties and ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the only authorized OSHA Training Institute Education Center headquartered in Northern California, has ... focused on providing occupational safety and health training to public sector employees. , ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Surgery, is excited to announce the arrival of the newest Sciton laser in ... the ability to use tunable non-ablative and ablative wavelengths for exceptional results. Outperforming ...
(Date:12/5/2016)... ... 05, 2016 , ... Researchers at Johns Hopkins All Children’s Hospital want to ... Over the course of three years, researchers will study concussions and changes in brain ... equipped with special sensors, will track the location and force of the hit. The ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Dec. 5 2016 United Kingdom Ophthalmic ... GlobalData,s new report, "United Kingdom Ophthalmic Diagnostic ... data on the United Kingdom Ophthalmic Diagnostic Equipment ... US dollars, volume (in units) and average prices ... (OCT), Retinal Ultrasound Imaging Systems, Corneal Topography Systems, ...
(Date:12/5/2016)... Dec. 5, 2016   Mallinckrodt Pharmaceuticals (NYSE: ... company, today announced that it received a perfect score ... (CEI), a national benchmarking survey and report on corporate ... transgender (LGBT) workplace equality, administered by the Human Rights ... major U.S. businesses which also earned top marks this ...
(Date:12/5/2016)... Dec. 5, 2016  Cornerstone Pharmaceuticals, Inc., a ... data from two Phase I trials evaluating its ... 58th annual meeting of the American Society of ... . The two datasets show encouraging efficacy ... leukemia (AML) and T-cell non-Hodgkin,s lymphoma (T-cell NHL), ...
Breaking Medicine Technology: